Does It MEK a Difference? Understanding Immune Effects of Targeted Therapy.

Clin Cancer Res 2015 Jul 29;21(14):3102-4. Epub 2015 May 29.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

BRAF inhibitor (BRAFi) treatment enhances antitumor immunity, but is associated with increased intratumoral PD-L1 expression. MEK inhibitors (MEKi) may alter T-cell function; however, recent studies demonstrate preserved T-cell infiltrate during treatment with BRAFi/MEKi. These data have important implications for combining BRAFi/MEKi and checkpoint blockade in the treatment of melanoma.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0363DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506225PMC
July 2015
15 Reads

Publication Analysis

Top Keywords

alter t-cell
4
meki alter
4
t-cell function
4
function studies
4
studies demonstrate
4
inhibitors meki
4
mek inhibitors
4
associated increased
4
increased intratumoral
4
intratumoral pd-l1
4
pd-l1 expression
4
demonstrate preserved
4
preserved t-cell
4
brafi/meki checkpoint
4
combining brafi/meki
4
checkpoint blockade
4
blockade treatment
4
treatment melanoma
4
implications combining
4
data implications
4

Similar Publications